Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States

Background: The US Food and Drug Administration has recently approved abaloparatide (ABL) for treatment of women with postmenopausal osteoporosis (PMO) at high risk of fracture. With increasing health care spending and drug prices, it is important to quantify the value of newly available treatment o...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Ann Pharmacother
Main Authors: Le, Quang A., Hay, Joel W., Becker, Russell, Wang, Yamei
Format: Artigo
Sprog:Inglês
Udgivet: SAGE Publications 2018
Fag:
Research Reports
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6311620/
https://ncbi.nlm.nih.gov/pubmed/30160186
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1060028018798034
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker